214 related articles for article (PubMed ID: 35296557)
21. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer.
Ishibashi Y; Tobisawa Y; Hatakeyama S; Ohashi T; Tanaka M; Narita S; Koie T; Habuchi T; Nishimura S; Ohyama C; Yoneyama T
Prostate; 2014 Nov; 74(15):1521-9. PubMed ID: 25154914
[TBL] [Abstract][Full Text] [Related]
22. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
Saad F; Fizazi K
Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
[TBL] [Abstract][Full Text] [Related]
23. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
[TBL] [Abstract][Full Text] [Related]
24. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
25. Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model.
Shen YC; Ghasemzadeh A; Kochel CM; Nirschl TR; Francica BJ; Lopez-Bujanda ZA; Carrera Haro MA; Tam A; Anders RA; Selby MJ; Korman AJ; Drake CG
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):113-125. PubMed ID: 29203894
[TBL] [Abstract][Full Text] [Related]
26. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
[TBL] [Abstract][Full Text] [Related]
27. Gut environment changes due to androgen deprivation therapy in patients with prostate cancer.
Kure A; Tsukimi T; Ishii C; Aw W; Obana N; Nakato G; Hirayama A; Kawano H; China T; Shimizu F; Nagata M; Isotani S; Muto S; Horie S; Fukuda S
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):323-330. PubMed ID: 35418210
[TBL] [Abstract][Full Text] [Related]
28. Restored Thymic Output after Androgen Blockade Participates in Antitumor Immunity.
Polesso F; Caruso B; Hammond SA; Moran AE
J Immunol; 2023 Feb; 210(4):496-503. PubMed ID: 36548468
[TBL] [Abstract][Full Text] [Related]
29. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
30. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.
Afshar-Oromieh A; Debus N; Uhrig M; Hope TA; Evans MJ; Holland-Letz T; Giesel FL; Kopka K; Hadaschik B; Kratochwil C; Haberkorn U
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2045-2054. PubMed ID: 29980832
[TBL] [Abstract][Full Text] [Related]
31. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
32. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
33. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
34. VSSP-activated macrophages mediate senescence and tumor inhibition in a preclinical model of advanced prostate cancer.
Alvarez-Arzola R; Bancaro N; Lai P; Attanasio G; Pellegrini L; Troiani M; Colucci M; Mosole S; Pasquini E; Alimonti A; Mesa C
Cell Commun Signal; 2023 Apr; 21(1):76. PubMed ID: 37055829
[TBL] [Abstract][Full Text] [Related]
35. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway.
Ardiani A; Gameiro SR; Kwilas AR; Donahue RN; Hodge JW
Oncotarget; 2014 Oct; 5(19):9335-48. PubMed ID: 25344864
[TBL] [Abstract][Full Text] [Related]
37. Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
Shigeta K; Kosaka T; Hongo H; Yanai Y; Matsumoto K; Morita S; Mizuno R; Shinojima T; Kikuchi E; Oya M
Int J Clin Oncol; 2019 May; 24(5):546-553. PubMed ID: 30604159
[TBL] [Abstract][Full Text] [Related]
38. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.
Filon MJ; Gillette AA; Yang B; Khemees TA; Skala MC; Jarrard DF
Prostate; 2022 Dec; 82(16):1547-1557. PubMed ID: 35980831
[TBL] [Abstract][Full Text] [Related]
40. Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition.
Pelliccia A; Capradossi F; Corsi F; Tarquini GD; Bruni E; Reichle A; Torino F; Ghibelli L
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
